Research Notes

Stay informed with the most recent market and company research insights.

A man sitting at a table with a glass of orange juice.

Research Notes

Through the worst of it

Amcor
3:27pm
February 7, 2024
AMC’s 1H24 result was below expectations at the underlying EBIT line but broadly in line at the underlying EPS line. Key positives: Cost out performance was strong with underlying EBIT margin falling only 20bp to 10.6% despite volumes declining 9%; 2Q24 should be the low point in earnings with an improvement expected from 3Q24 onwards. Key negatives: 2Q24 volumes (-10%) were weaker than management’s expectations for a decline of ~8% at the beginning of the quarter; AMC expects customer destocking in global healthcare and North America beverages to continue in 3Q24 and possibly into 4Q24. While 2H24 underlying EPS guidance was slightly softer than prior guidance, management has reaffirmed FY24 expectations for underlying EPS of between US67-71cps and underlying free cash flow of between US$850-950m. Our FY24-26F underlying EPS falls by 2%, although our target price rises to $15.65 (from $15.20) largely due a model roll-forward to FY25 forecasts. Add retained.

Benign earnings growth and elevated multiple, hold

CSR Ltd
3:27pm
February 7, 2024
Whilst the announced settlement timetable for Stage 3 at Horsley Park (industrial estate) has little impact on our valuation, given our Property division is valued on an NPV of future cashflows, it does suggest the business could be delivering c.60% EBIT margins at West Schofields and Badgerys Creek as they are developed in coming years. The recent announcement does however give cause to reassess our valuation, given the stock is up 18% since Nov-23. To that end CSR is now trading at a PE ratio of c.16x, one standard deviation above its long run average and with the business unlikely to grow earnings over the next two years, we see the stock as fully priced, hence our decision to downgrade to a Hold rating, despite incrementally increasing our target price to $6.90/sh.

New products to underpin growth into 2024

Control Bionics
3:27pm
February 7, 2024
Following a successful A$2.7m rights issue, CBL is now funded into 2024 with new products (DROVE and NeuroStrip) adding to the improving sales position. Australia delivered solid revenue growth in 1H24 (despite NDIS delays) and momentum is expected to continue in 2H. However, sales in North America in 1H24 were flat although management expects an improvement in 2H. We are moving a number of our early stage development companies to the new ‘Keeping Stock’ format which enables us to continue to provide regular and timely updates. We will cease providing a rating, valuation and forecasts. Therefore, our previous forecasts, target price and recommendation should no longer be relied upon for investment decisions.

Remaining steady

Dexus Convenience Retail REIT
3:27pm
February 6, 2024
DXC’s 1H24 result delivered stable portfolio metrics with the focus during the half on maintaining balance sheet resilience. Gearing at c32%. Dec-23 revaluations saw cap rates expand 20bps (-1.7% portfolio impact). NTA stands at $3.63 vs $3.75 at Jun-23. FY24 guidance has been tightened slightly and now comprises FFO and DPS of 20.8-21.1c (was 20.7-21.1c). This equates to a distribution yield of approx. 8%. DXC remains an Add with a revised price target of $3.23.

More than a gut feeling

Microba Life Sciences
3:27pm
February 6, 2024
Microba Life Sciences (MAP) is an emerging leader in the microbiome industry specialising in gut health testing and therapeutic development. The company provides a comprehensive end-to-end solution, encompassing internally developed tests and therapeutic candidates generated via its discovery engine and artificial intelligence (AI) capabilities. In collaboration with renowned microbiome specialists worldwide, MAP stands out as a distinctive value proposition, offering high-margin products and opportunities through its therapeutics discovery platform. The expanding testing services business and increasing awareness among healthcare professionals about the pivotal role of the microbiome are driving a surge in demand. This heightened awareness is fueling increased interest in microbiome-related services, products, and advancements, indicating a growing recognition of its impact on overall health across diverse medical applications. We initiate coverage of MAP with a valuation and target price of A$0.35 p/s with a Speculative Buy recommendation.

Building towards the next earnings step-up

Pinnacle Investment Mgmt
3:27pm
February 2, 2024
Group NPAT was flat on the pcp at A$30.2m and in line with expectations. Affiliate NPAT contribution was +31% on pcp but -9% ex-performance fees. Group FUM closed at A$100.1bn, up 9% over the half. Starting 2H24 FUM is up ~8% on 1H24 average (flows and market uplift late in the half). 1H24 Net flows comprised: retail +A$1.8bn; domestic insto -A$0.4bn; and offshore +A$3.1bn. QoQ improvement was experienced (1Q A$0.2bn; 2Q A$4.3bn). PNI’s near-term valuation (~26x FY24 PE) sees the stock susceptible to short-term volatility. However, PNI has structural growth drivers and we see the medium-term (FY25/26) earnings step-up is supported by: a return to improved flows; higher performance fee FUM; significant operating leverage on improved FUM; leveraging the recent investment spend; and the eventual addition of new managers.

Executing its strategy

MoneyMe
3:27pm
February 1, 2024
MoneyMe (MME) has released a 1H24 trading update, which whilst brief, did highlight the continued execution of management’s strategy to improve the overall credit quality of the book itself (average Equifax score 741) and focus on profitability. The gross loan book remained stable at A$1.2bn, generating revenue of >A$105m (-~13% on pcp) and a statutory NPAT of A$6m. Our FY24F-FY26F EBITDA is lowered by ~3-9% on slight adjustments to gross loan book growth rates, loss rates and book yield. Our DCF/PB blended valuation (equal-weighted) and price target remains unchanged at A$0.25 on the above changes offset by timing impacts of our DCF.

Execution in the US required

Credit Corp
3:27pm
January 31, 2024
CCP’s 1H24 underlying NPAT of A$33.5m (+5% on pcp) missed consensus expectations (>15%) on higher lending provisioning; and high cost growth. CCP held NPAT guidance. The mid-point looks achievable (implied 2H24 NPAT ~A$51.5m), with 2H Lending volumes the main swing factor. Despite the ‘miss’, CCP’s FY25/26 earnings outlook remains largely unchanged. However, the composition skews further to Consumer Lending; and trust in the USA execution is required (only slight incremental US ‘evidence’ in this result). Backing management’s execution in delivering on USA divisional growth expectations over FY25/26 is needed. We think the valuation point (11.5x FY25PE) provides enough upside and risk/reward to do so. Add maintained.

Hitting its targets

Airtasker
3:27pm
January 31, 2024
Airtasker (ART) released a broadly positive 2Q24 trading update in our view, which saw an +8% increase in group revenue to A$12.2m, and the business achieving positive free cash flow for the period. We make upward revisions to our FY25-26F revenue estimates on an improved take-rate (details below). Our DCF/Multiples derived price target increases marginally to A$0.54 (from A$0.53). Add maintained.

Share price over reaction to an exciting outlook

ImpediMed
3:27pm
January 31, 2024
IPD share price has come under selling pressure after the release of its 2Q24 cashflow report which was below expectation. However we believe this is an overreaction with excellent progress being made with private payor coverage. IPD highlight that 13 states in the US have reached critical mass (ie 80% of population covered for reimbursement from private payors or Medicare). The target is that 85% of the US will be providing coverage by the end of FY24. Following a change in management estimates of revenue recognition to equal monthly payments across the term of each contract we have revised our revenue forecast. As a result our DCF based valuation has reduced to A$0.20 (was A$0.22). we maintain our Speculative Buy recommendation.

News & Insights

The US economy is growing strongly at 2.34% in Q2 2025 but is expected to slow to 1.4% in 2025, with falling interest rates and a weaker US dollar likely to boost commodity prices, benefiting Australian markets. Michael Knox discusses.

We think the US economy is currently experiencing solid growth, with data from the Chicago Fed  National Activity Index indicating an annual growth rate of just above  2%. This aligns with projections from other parts of the Federal Reserve System, such as the New York Fed. The New York Fed’s weekly Nowcast, updated every Friday, estimates that for the second quarter of 2025, the US economy is growing at an annualised rate of 2.34%, surpassing the 2% mark. This robust growth is consistent with our model’s view that the US economy is now performing strongly. However, we anticipate a slowdown in the second half of 2025.

On 18 June the Fed released its Summary of Economic Projections  with the Federal Reserve’s  forecasting US GDP growth to drop to 1.4% in 2025, down from their March estimate of 1.7%. Looking further ahead, growth is expected to pick up slightly to 1.6% in 2026 and 1.8% in 2027, aligning with the long-term trend growth rate of around 1.8%. We believe this recovery trend could be even  higher,  driven by reduced regulation under the second Trump administration and aggressive tax write-offs for companies building factories in the US, allowing 100% write-offs for equipment and buildings in the first year. This policy should foster stronger systemic growth.

Economic Projections of the Federal Reserve

The Fed expects that as the economy slows,  unemployment is projected to rise to 4.5% from the current level of 4.2%. Inflation, measured by the Consumer Price Index (CPI), is running at 3.5% this year, approximately 50 basis points higher than the Personal Consumption Expenditures (PCE) index of 3.0%, with 1.6% of this  inflation  attributed to tariffs. The Fed expects PCE Inflation  to ease to 2.4% in 2026 and 2.1% in 2027. The Federal Reserve anticipates cutting the effective  federal funds rate, currently at 433 basis points (according to the New York Fed), by 50 basis points by the end of 2025, followed by an additional 25 basis points in each of the next two years. This aligns with our own Fed Funds rate  model’s current equilibrium federal funds rate of  3.85% . The Fed Outlook  supports our scenario of a slowing US economy and rate cuts in the second half of 2025 and beyond. A falling US dollar is then expected to exert upward pressure on commodity prices, benefiting Australian Equity markets.

Taking questions during the Press Conference after releasing the Fed statement  ,Federal Reserve Chair Jay Powell,   addressed the certainty and uncertainty surrounding the inflationary effects of tariffs. Initially, at the start of 2025, the inflationary impact of tariff policies was unclear, but three months of favourable inflation data have provided this clarity, indicating that the inflationary effects are less severe than anticipated. Powell noted that the Feds own uncertainty on the inflationary effects of  tariffs  peaked in April 2025, and the Federal Reserve now has a clearer understanding that  the inflation effects, are lower than initially expected.

The Fed view  supports our own scenario of a slowing US economy in the second half of 2025, allowing for Fed rate cuts  . This in turn should then lead to  a falling US dollar, which we in turn  expect to drive rising commodity prices.

Read more
The Your Wealth publication is our half yearly scrutiny into current affairs for wealth management. Our latest Issue 29 is out now.

The second half of 2025 will be an interesting time for everyone. Geopolitical uncertainty prevails. How will all of this impact the Australian investor and in particular, their wealth and retirement savings? Whether you are an accumulator, saving for short- and long-term goals, or a retiree, hoping for a comfortable retirement, the ability to manage this uncertainty will be key.

When we published the previous Your Wealth – First Half 2025, the Division 296 Bill (Div296) was also facing uncertainty. The Bill was eventually blocked in the Senate prior to the Federal Election. The Labor Party succeeded in winning so it’s Ground Hog Day for Div296. The Government doesn’t have the numbers in the Senate to pass the Bill without support from other parties. The Greens are the likely negotiating party but will undoubtably have their own agenda. Regardless, there is a high probability this legislation will be passed once Parliament resumes.

Our message to our clients is to wait until we know more details and to not act in haste.

In addition to our Feature Article which provides further insights on Div296, this edition also Spotlights the Aged Care changes due this year, with the start date pushed back to 1 November.

We hope readers enjoy this edition of Your Wealth.


Morgans clients receive exclusive insights such as access to our latest Your Wealth publication. Contact us today to begin your journey with Morgans.

      
Contact us
      
Read more
Michael Knox, Chief Economist, reveals how the OECD and RBA’s outdated assumptions about global trade fail to account for China’s Marxist-Leninist economic strategies.

This morning, I was asked to discuss Sarah Hunter’s presentation from yesterday. Sarah, the Assistant Governor and Chief Economist at the Reserve Bank of Australia (RBA), delivered a detailed and competent discussion on the conventional view of tariffs’ impact on the international economy. She highlighted that tariffs typically increase inflation and reduce economic output, a perspective echoed by the OECD in a similar presentation overnight. Sarah’s analysis focused on the potential shocks tariffs could cause, particularly their effects on GDP and inflation.

Drawing on my experience as an Australian trade commissioner and my work in Australian embassies, I found her presentation particularly interesting. My background allowed me to bring specialist knowledge to the conversation, which I believe gave me an edge. Notably, I observed that the RBA seems to lack analysts closely tracking individual policymakers in the Trump administration, such as Scott Bessent, whose views on tariffs and competition differ from the general assumptions. The conventional view assumes a world of perfectly competitive countries adhering to international trade rules and unlikely to engage in conflict—a scenario that doesn’t align with the current global trade environment, especially between China and the United States.

China, operating as a Marxist-Leninist economy, aims to dominate global markets by building monopolies in areas like rare earths, nickel, copper, and other base metals. It maintains a managed exchange rate, despite promises to the International Monetary Fund for a freely floating currency. If China allowed its currency, the RMB, to float, it would likely appreciate significantly, increasing imports and reducing its trade surplus. This would create a more balanced international trade environment, potentially reducing the need for other countries to impose tariffs. However, major institutions like the OECD and RBA seem to misjudge the nature of this trade shock, relying on outdated assumptions about global trade dynamics.

The international community also appears to overlook specific U.S. policy intentions, such as those articulated by figures like Peter Navarro and Scott Bessent. The U.S. aims to use tariffs selectively to bolster industries like pharmaceuticals, precision manufacturing, and motor vehicles. This misunderstanding leads public institutions to perceive unspecified risks, as reflected in Sarah’s otherwise able presentation. Because the RBA and similar institutions view the world as fraught with undefined risks, they are inclined to keep interest rates low, responding to perceived threats rather than an equilibrium model.

Interestingly, data from the U.S. economy contradicts the expected negative impacts of tariffs. The Chicago Fed National Activity Indicator, a reliable gauge of economic growth since the 2008 financial crisis, shows U.S. growth above the long-term trend for the first four months of this year. This suggests resilience despite tariff-related shocks. Ideally, growth will slow later this year, prompting the Federal Reserve to cut rates, facilitating a soft landing and a decline in the U.S. dollar to boost global commodity prices. However, this nuanced outlook wasn’t evident in yesterday’s presentation.

Moreover, the anticipated rise in U.S. inflation due to tariffs isn’t materialising. Scott Bessent recently noted that U.S. CPI inflation is lower than expected, with core inflation shown as the (16% trimmed mean) at 3% for the past two months . Core inflation  excluding  food and energy CPI  is only at 2.8%. This suggests that Chinese suppliers are absorbing tariff costs to maintain market share, rather than passing them on as higher prices. Recent Chinese data supports this, showing a slight decline in manufacturing confidence and coal consumption, indicating reduced factory output and electricity use. This points to a modest slowdown in China’s economy. So far the expected negative effects on U.S. prices and output are not occurring.

In summary, the fears expressed by institutions like the RBA and OECD about the Trump administration’s trade policies appear overstated. The U.S. economy is not experiencing the predicted declines in output or increases in inflation. While these effects may emerge later, the current data suggests that the risks are not as severe as anticipated, highlighting a disconnect between theoretical models and real-world outcomes.

Read more